首页膀胱肿瘤病因/危险因素证据详情

The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies

原文: 2017 年 发布于 Int J Clin Pharmacol Ther 浏览量:167次

作者: Zhang Z. Fan W. Deng Q. Tang S. Wang P. Xu P. Wang J. Yu M.

作者单位: Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium - simone.albisinni@erasme.ulb.ac.be. Division of Urology, VCU Health Center and McGuire VA Medical Center, Richmond, VA, USA. Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. Department of Urology, Hôtel Dieu de France, Saint Joseph University, Beyrouth, Lebanon. Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. Department of Urology, Humanitas Gavezzani, Bergamo, Italy. Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

归属分类: 膀胱肿瘤病因/危险因素证据

DOI: 10.1007/s00330-020-06802-z

文献简介

OBJECTIVE: To assess the prognostic and clinicopathological characteristics of CD147 in human bladder cancer. METHODS: Studies on CD147 expression in bladder cancer were retrieved from PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and the WanFang databases. Outcomes were pooled with meta-analyzing softwares RevMan 5.3 and STATA 14.0. RESULTS: Twenty-four studies with 25 datasets demonstrated that CD147 expression was higher in bladder cancer than in non-cancer tissues (OR=43.64, P<0.00001). Moreover, this increase was associated with more advanced clinical stages (OR=73.89, P<0.0001), deeper invasion (OR=3.22, P<0.00001), lower histological differentiation (OR=4.54, P=0.0005), poorer overall survival (univariate analysis, HR=2.63, P<0.00001; multivariate analysis, HR=1.86, P=0.00036), disease specific survival (univariate analysis, HR=1.65, P=0.002), disease recurrence-free survival (univariate analysis, HR=2.78, P=0.001; multivariate analysis, HR=5.51, P=0.017), rate of recurrence (OR=1.91, P=0.0006), invasive depth (pT2 ∼ T4 vs. pTa ∼ T1; OR=3.22, P<0.00001), and histological differentiation (low versus moderate-to-high; OR=4.54, P=0.0005). No difference was found among disease specific survival in multivariate analysis (P=0.067), lymph node metastasis (P=0.12), and sex (P=0.15). CONCLUSION: CD147 could be a biomarker for early diagnosis, treatment, and prognosis of bladder cancer.

热门文献